Eyedrops containing SA9000 prodrugs result in sustained reductions in intraocular pressure in rabbits

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 3, 2009, Pages 179-186

  Arnold, John J ^a,d   Choksi, Yash ^a   Chen, Xin ^b   Shimazaki, Atsushi ^c   Hatten, John ^b   Toone, Eric J ^b   Epstein, David L ^a   Challa, Pratap ^a,e  

^a DUKE UNIVERSITY EYE CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SANTEN PHARMACEUTICAL CO LTD   (Japan)

^d SAMFORD UNIVERSITY   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; ETACRYNIC ACID; EYE DROPS; PRODRUG; SA 900; SA 9000; THIOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; EXPERIMENTAL RABBIT; EYE IRRITATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAOCULAR PRESSURE; MALE; NONHUMAN;

ADMINISTRATION, TOPICAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CINNAMATES; CONJUNCTIVA; CONJUNCTIVAL DISEASES; CORNEA; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ETHACRYNIC ACID; HYPEREMIA; INTRAOCULAR PRESSURE; MALE; OPHTHALMIC SOLUTIONS; PERMEABILITY; PRODRUGS; RABBITS;

EID: 66249094899     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0107     Document Type: Article

References (23)

1. Frishman, W.H., Fuksbrumer, M.S., and Tannenbaum, M. Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension. J. Clin. Pharmacol. 34(8):795-803, 1994.
2. Urtti, A. Delivery of antiglaucoma drugs: ocular vs systemic absorption. J. Ocul. Pharmacol. 10(1):349-357, 1994.
3. Zimmerman, T.J. Topical ophthalmic beta blockers: a comparative review. J. Ocul. Pharmacol. 9(4):373-384, 1993.
4. Eisenberg, D.L., Toris, C.B., and Camras, C.B. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv. Ophthalmol. 47(Suppl 1):S105-S115, 2002.
5. Perry, C.M., McGavin, J.K., Culy, C.R., et al. Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging. 20(8):597-630, 2003.
6. Woodward, D.F., and Gil, D.W. The inf ow and outf ow of antiglaucoma drugs. Trends Pharmacol. Sci. 25(5):238-241, 2004.
7. Epstein, D.L., Freddo, T.F., Bassett-Chu, S., et al. Inf uence of ethacrynic acid on outf ow facility in the monkey and calf eye. Invest. Ophthalmol. Vis. Sci. 28(12):2067-2075, 1987.
8. Liang, L.L., Epstein, D.L., de Kater, A.W., et al. Ethacrynic acid increases facility of outf ow in the human eye in vitro. Arch. Ophthalmol. 110(1):106-109, 1992.
9. Melamed, S., Kotas-Neumann, R., Barak, A., et al. The effect of intracamerally injected ethacrynic acid on intraocular pressure in patients with glaucoma. Am. J. Ophthalmol. 113(5):508-512, 1992.
10. Tingey, D.P., Ozment, R.R., Schroeder, A., et al. The effect of intracameral ethacrynic acid on the intraocular pressure of living monkeys. Am. J. Ophthalmol. 113(6):706-711, 1992.
11. Epstein, D.L., Hooshmand, L.B., and Epstein, M.P. Thiol adducts of ethacrynic acid increase outf ow facility in enucleated calf eyes. Curr. Eye Res. 11(3):253-258, 1992.
12. Tingey, D.P., Ozment, R.R., Schroeder, A., et al. The effect of intracameral ethacrynic acid on the intraocular pressure of living monkeys. Am. J. Ophthalmol. 113(6):706-711, 1992.
13. Epstein, D.L., Hooshmand, L.B., and Epstein, M.P. Thiol adducts of ethacrynic acid increase outf ow facility in enucleated calf eyes. Curr. Eye Res. 11(3):253-258, 1992.
14. Tingey, D.P., Schroeder, A., Epstein, M.P., et al. Effects of topical ethacrynic acid adducts on intraocular pressure in rabbits and monkeys. Arch. Ophthalmol. 110(5):699-702, 1992.
15. Xu, S., Roychowdhury, S., Gaskin, F., et al. Ethacrynic acid inhibition of microtubule assembly in vitro. Arch. Biochem. Biophys. 296(2):462-467, 1992 Aug 1.
16. Erickson-Lamy, K., Schroeder, A., and Epstein, D.L. Ethacrynic acid induces reversible shape and cytoskeletal changes in cultured cells. Invest. Ophthalmol. Vis. Sci. 33(9):2631-2640, 1992.
17. O'Brien, E.T., Kinch, M., Harding, T.W., et al. A mechanism for trabecular meshwork cell retraction: ethacrynic acid initiates the dephosphorylation of focal adhesion proteins. Exp. Eye Res. 65(4):471-483, 1997.
18. Shimazaki, A., Suhara, H., Ichikawa, M., et al. New ethacrynic acid derivatives as potent cytoskeletal modulators in trabecular meshwork cells. Biol. Pharm. Bull. 27(6):846-850, 2004 Jun.
19. Rao, P.V., Shimazaki, A., Ichikawa, M., et al. Effects of novel ethacrynic acid derivatives on human trabecular meshwork cell shape, actin cytoskeletal organization, and transcellular fluid flow. Biol. Pharm. Bull. 28(12):2189-2196, 20 05.
20. Shimazaki, A., Ichikawa, M., Rao, P.V., et al. Effects of the new ethacrynic acid derivative SA9000 on intraocular pressure in cats and monkeys. Biol. Pharm. Bull. 27(7):1019-1024, 2004.
21. Babiole, M., Wilhelm, F., and Schoch, C. In vitro corneal permeation of unoprostone isopropyl (UI) and its metabolism in the isolated pig eye. J. Ocul. Pharmacol. Ther. 17(2):159-172, 2001.
22. Kaur, I.P., and Kanwar, M. Ocular preparations: the formulation approach. Drug Dev. Ind. Pharm. 28(5):473-493, 2002.
23. Lawrence, M.S., and Miller, J.W. Ocular tissue permeabilities. Int. Ophthalmol. Clin. 44(3):53-61, 2004.